

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>G1 EXECUTION SERVICES, LLC</u> (Last) (First) (Middle) 175 W. JACKSON BLVD., SUITE 1700 501 PLAZA 2 (Street) CHICAGO IL 60604 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>ACHILLION PHARMACEUTICALS INC</u> [ACHN]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 01/28/2020	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	01/28/2020		J ⁽¹⁾		10,917	D	\$6.3 ⁽¹⁾	0	D ⁽²⁾⁽⁴⁾	
Common Stock	01/28/2020		J ⁽¹⁾		14,115,498	D	\$6.3 ⁽¹⁾	0	D ⁽³⁾⁽⁴⁾	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date					

1. Name and Address of Reporting Person*
G1 EXECUTION SERVICES, LLC
 (Last) (First) (Middle)
 175 W. JACKSON BLVD., SUITE 1700
 501 PLAZA 2
 (Street)
 CHICAGO IL 60604
 (City) (State) (Zip)

1. Name and Address of Reporting Person*
SUSQUEHANNA FUNDAMENTAL INVESTMENTS, LLC
 (Last) (First) (Middle)
 401 CITY AVENUE, SUITE 220
 (Street)
 BALA CYNWYD PA 19004
 (City) (State) (Zip)

1. Name and Address of Reporting Person*
SUSQUEHANNA SECURITIES, LLC
 (Last) (First) (Middle)

401 CITY AVENUE, SUITE 220

(Street)

BALA CYNWYD PA

19004

(City)

(State)

(Zip)

Explanation of Responses:

1. Disposed of pursuant to an Agreement and Plan of Merger among Achillion Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc. and Beagle Merger Sub, Inc. In addition to the cash consideration of \$6.30 per share, each shareholder will also receive one contingent value right ("CVR") per share. Each CVR represents the right to receive contingent cash payments of \$1.00 upon the achievement of a certain clinical trial milestone with respect to ACH-5228 and \$1.00 upon the achievement of a certain regulatory approval milestone with respect to ACH-4471.
2. These securities are directly owned by G1 Execution Services, LLC ("G1X").
3. These securities are directly owned by Susquehanna Securities, LLC ("SS").
4. G1X, Susquehanna Fundamental Investments, LLC ("SFNDI") and SS are affiliated entities under common ownership. G1X, SFNDI and SS each disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interest therein, and this report shall not be deemed an admission that any of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

G1 Execution Services, LLC

By: /s/ Brian Sopinsky Name: 01/30/2020

Brian Sopinsky Title: Secretary

Susquehanna Fundamental

Investments, LLC By: /s/ Brian

Sopinsky Name: Brian

01/30/2020

Sopinsky Title: Assistant

Secretary

Susquehanna Securities, LLC

By: /s/ Brian Sopinsky Name: 01/30/2020

Brian Sopinsky Title: Secretary

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.